Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be
administered intravenously to people who have suffered an acute spinal cord fracture. The
goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this
population. Outcome measures will include bone density determinations over a one year period.